SYRESpyre Therapeutics, Inc.

$3B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$22M

Net Income

-$21M

EPS (Diluted)

$-16.52

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$83M

Total Liabilities

$23M

Stockholders' Equity

$60M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$22M	-$15M	-43.1%
Net Income	-$21M	-$15M	-44.3%

SYRE Q4 2019 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena